Bayer 📈 análisis fundamental y técnico

Bayer análisis fundamental y técnico de farmaceutica Alemana
/
Volume | Market Cap | Shares | PEG Ratio | EPS

COMPAÑÍA INFO

Bayer AG es una compañía de ciencias de la vida. Los segmentos de la compañía son productos farmacéuticos, salud del consumidor, ciencias de la cosecha, salud animal y Covestro.

El segmento de productos farmacéuticos se dedica al desarrollo de productos farmacéuticos recetados; anticonceptivos y productos médicos, como sistemas de inyección y agentes de contraste para procedimientos de diagnóstico.

El segmento de Salud del Consumidor se dedica al desarrollo de medicamentos de venta libre, productos dermatológicos y suplementos nutricionales.


BAYER: Relaciones con los inversores – Informe anual
El Consejo de Administración
Presidente CEO: Werner Baumann.
Componentes del consejo de administración de BAYER.


City Country Website Full Time Employees Total Cash

HISTORIAL DE PRECIOS BAYER

52 Week Low % Change from 52 Week Low 52 Week High % Change from 52 Week High 50 Days Moving Average 200 Days Moving Average

ORDENES EN MERCADO

Bid Size Bid Ask Ask Size

ANÁLISIS TÉCNICO DE BAYER


RECOMENDACIONES DE BAYER


COMPETIDORES DE BAYER

BAYN.DE SAN.PA GRF.MC
Name
Change
% Change
Market Cap
% Change from 52 Week Low
% Change from 52 Week High
Shares Outstanding
Volume
Dividend Rate

ANÁLISIS FUNDAMENTAL DE BAYER

Profit Margins Gross Margins EBITDA Margins Operating Margins
Total Cash Total Cash Per Share Free Cashflow Book Value
Bid Size Average Daily Volume 10 Day Average Daily Volume 3M Trailing Annual Dividend Yield EBITDA
Market Cap Net Income To Common EPS (TTM) Total Revenue
Float Shares Shares Outstanding Revenue Per Share P/E Ratio
Earnings Growth Revenue Growth Earnings Quarterly Growth
Return On Assets Return On Equity Operating Cashflow Gross Profits
Price To Book Enterprise To Revenue Enterprise To EBITDA Enterprise Value
Debt To Equity Total Debt Recommendation Mean Recommendation Key

RSS Bayer IR Newsfeed: Investor News

  • 13.01.20: Not intended for U.S. and UK Media enero 12, 2020
    Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®Underlining Bayer's commitment in the field of women's health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit rangemehr ...
  • 10.12.19: Bayer to significantly step-up its sustainability efforts diciembre 9, 2019
    Bayer to significantly step-up its sustainability efforts2030 target to be carbon neutral in own operations / Ambitious 2030 objectives for access to health and nutrition in low- and middle-income countries and underserved communities / Measurable sustainability targets to be incorporated into management compensationmehr ...
  • 29.11.19: Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets noviembre 28, 2019
    Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real AssetsFurther step in Bayer's efforts to sharpen focus on core businessmehr ...
  • 25.11.19: Not intended for U.S. and UK Media noviembre 24, 2019
    Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolismAdding treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis / Submission based on results from phase 3 EINSTEIN-Jr. study showing convincing efficacy […]
  • 18.11.19: Not intended for U.S. and UK Media noviembre 17, 2019
    Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpointVericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart […]
  • 07.11.19: NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN noviembre 6, 2019
    Bayer refinances 1.75 billion euro hybrid bondNew issue of two tranches with a non-call period of 5.5 and 8 years combined with a tender offer for Bayer's existing hybrid bondmehr ...
  • 04.11.19: Bayer completes sale of Dr. Scholl's™ brand to Yellow Wood Partners noviembre 3, 2019
    Bayer completes sale of Dr. Scholl's™ brand to Yellow Wood Partnersmehr ...
  • 30.10.19: Third quarter of 2019 octubre 29, 2019
    Bayer: Encouraging business performance across all divisions - agreements signed to divest Currenta and Animal HealthGroup sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros / EBITDA before special items advances by 7.5 percent to 2.291 billion euros / Crop Science reports higher sales and substantial earnings growth / Pharmaceuticals increases […]
  • 14.10.19: Not intended for U.S. and UK Media octubre 13, 2019
    U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patientsA new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S […]
  • 01.10.19: Ertharin Cousin to become member of Bayer AG Supervisory Board septiembre 30, 2019
    Ertharin Cousin to become member of Bayer AG Supervisory BoardInternational expert in the area of nutrition and agriculture / Cousin succeeds Thomas Ebeling, who stepped down at the end of Septembermehr ...

Dejar respuesta

Please enter your comment!
Please enter your name here